168 filings
8-K
HGENQ
Humanigen, Inc
8 Jan 24
Entry into a Material Definitive Agreement
5:02pm
8-K
HGENQ
Humanigen, Inc
14 Sep 23
Departure of Directors or Certain Officers
4:01pm
8-K
HGENQ
Humanigen, Inc
24 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:25pm
8-K
HGENQ
Humanigen, Inc
19 Apr 23
Other Events
6:00am
8-K
HGENQ
Humanigen, Inc
6 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:45pm
8-K
w9120
13 Mar 23
Regulation FD Disclosure
6:00am
8-K
ats4c0tcddmwpdqk
2 Mar 23
Other Events
5:15pm
8-K
3fpdqfk bxwd96ktn
24 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:48pm
8-K
wkam z4zqp
22 Dec 22
Entry into a Material Definitive Agreement
5:20pm
8-K
edlu3
14 Nov 22
Humanigen Reports Third Quarter 2022 Financial Results
4:16pm
8-K
zehn1x0mruvdvemv9c
6 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:13pm
8-K
x39h s9385fcqt5umr
29 Sep 22
Departure of Directors or Certain Officers
5:15pm
8-K
6j40p8d jrnw
2 Sep 22
Departure of Directors or Certain Officers
4:07pm
8-K
nbv5108 vwymuh31su
26 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
hzepzjlr40ptycuag
12 Aug 22
Humanigen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
cao2l9d5vpjs7j6s
26 Jul 22
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
4:05pm
8-K
zjc97vn
13 Jul 22
Humanigen receives preliminary topline data from NIH/NIAID study of lenzilumab in ACTIV-5/BET-B
6:01am
8-K
1df vjoxwj6
30 Jun 22
Other Events
8:24am
8-K
16hjs ziyq
10 Jun 22
Submission of Matters to a Vote of Security Holders
4:56pm
8-K
ie9xkd9 z2
5 May 22
Humanigen Reports First Quarter 2022 Financial Results
4:05pm